Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss

被引：38
作者：
Popov, Violeta B. [1 ]
Lim, Joseph K. [2 ]
机构：
[1] NYU, Sch Med, Div Gastroenterol, New York, NY USA
[2] Yale Univ, Sch Med, Sect Digest Dis, Yale Liver Ctr, 333 Cedar St,LMP 1080, New Haven, CT 06520 USA
来源：
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY | 2015年 / 3卷 / 03期
关键词：
Fatty liver; Nonalcoholic steatohepatitis; Weight loss; Exercise; Pharmacotherapy; Endoscopic therapy; Bariatric surgery;
D O I：
10.14218/JCTH.2015.00019
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nonalcoholic fatty liver disease (NAFLD) represents a rapidly growing cause of chronic liver disease in the United States and is associated with significant morbidity and mortality, including progression to liver cirrhosis and hepatocellular carcinoma. NAFLD comprises a spectrum of liver conditions, ranging from simple steatosis to steatosis with inflammation (steato-hepatitis) and progressive fibrosis. Weight loss represents a first line therapeutic modality for the management of NAFLD. Herein, we review the evidence base for medical, surgical, and endoscopic approaches to weight loss and their potential impact on the natural history of NAFLD. (C) 2015 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.
引用
收藏
页码：230 / 238
页数：9
相关论文
共 82 条
  • [1] The natural history of nonalcoholic fatty liver disease: A population-based cohort study
    Adams, LA
    Lymp, JF
    St Sauver, J
    Sanderson, SO
    Lindor, KD
    Feldstein, A
    Angulo, P
    [J]. GASTROENTEROLOGY, 2005, 129 (01) : 113 - 121
  • [2] The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
    Adams, LA
    Sanderson, S
    Lindor, KD
    Angulo, P
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (01) : 132 - 138
  • [3] Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
    Angelico, F.
    Burattin, M.
    Alessandri, C.
    Del Ben, M.
    Lirussi, F.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01):
  • [4] Angulo Paul, 2005, Rev Gastroenterol Mex, V70 Suppl 3, P52
  • [5] Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
    Argo, Curtis K.
    Caldwell, Stephen H.
    [J]. CLINICS IN LIVER DISEASE, 2009, 13 (04) : 511 - +
  • [6] Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
    Argo, Curtis K.
    Northup, Patrick G.
    Al-Osaimi, Abdullah M. S.
    Caldwell, Stephen H.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 51 (02) : 371 - 379
  • [7] Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
    Armstrong, Matthew J.
    Barton, Darren
    Gaunt, Piers
    Hull, Diana
    Guo, Kathy
    Stocken, Deborah
    Gough, Stephen C. L.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    [J]. BMJ OPEN, 2013, 3 (11):
  • [8] Armstrong MJ, 2015, INT LIV C VIENN AUST
  • [9] Diets and nonalcoholic fatty liver disease: The good and the bad
    Asrih, Mohamed
    Jornayvaz, Francois R.
    [J]. CLINICAL NUTRITION, 2014, 33 (02) : 186 - 190
  • [10] Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
    Baffy, Gyoergy
    Brunt, Elizabeth M.
    Caldwell, Stephen H.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1384 - 1391
123456789